Patrick Machado

Mr. Machado has served as one of the directors since June 2014. Mr. Machado also currently serves as board chair at Adverum Biotechnologies, and as a director at Arcus Biosciences, Turning Point Therapeutics and Xenon Pharmaceuticals, all of which are public pharmaceutical companies, as well as Acelyrin, Roivant Sciences Ltd. and Turnstone Biologics, private biopharmaceutical companies. Mr. Machado is a co-founder of Medivation, Inc., a biopharmaceutical company, and served on its Board of Directors from April 2014 until the company was acquired by Pfizer in September 2016. Prior to his retirement in April 2014, Mr. Machado served as Medivation’s Chief Financial Officer since its inception in September 2003 and as its Chief Business Officer since December 2009. From 1998 until 2001, Mr. Machado was employed by ProDuct Health, Inc., a privately held medical device company: as Vice President, Chief Financial Officer, and General Counsel from 1998 to 2000, and as Senior Vice President and Chief Financial Officer from 2000 to 2001. From 2001 until 2002, Mr. Machado served as a consultant to Cytyc Corporation, to assist with transitional matters related to Cytyc Corporation’s acquisition of ProDuct Health, Inc. Mr. Machado received a J.D. from Harvard Law School and a B.A. and a B.S. in German and Economics, respectively, from Santa Clara University.